Responsibility in Drug Advertising Act of 2024

HR 9142, the Responsibility in Drug Advertising Act of 2024, prohibits drug manufacturers from advertising new drugs directly to consumers for the first three years after FDA approval. After this initial period, the FDA may ban such advertising if post-approval studies show significant health risks. Manufacturers can request a waiver during the third year if they demonstrate public health benefits, but the FDA retains authority to restrict advertising based on safety data. The bill requires the FDA to update advertising regulations within one year of enactment, applying specifically to new drugs approved under standard FDA review.